Kryxana 200 mg FC tablet.
PDF Leaflet Revision Date: 13 May 2024
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of HR-positive, HER2-negative advanced or metastatic breast cancer.
Dosage (summary)
600 mg once daily for 21 days, followed by 7 days off.
Special Populations
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy and breastfeeding; use effective contraception.
Key Drug Interactions
- Strong CYP3A4 inhibitors
- Tamoxifen
Contraindications
- Hypersensitivity to ribociclib or excipients
- Congenital long QT syndrome
Common side effects
- Neutropenia
- Nausea
- Fatigue
- Diarrhea
- Rash
Counselling Points
- Take at the same time each day
- Report fever or signs of infection
- Avoid grapefruit juice
Serious warnings
- QT prolongation
- Hepatobiliary toxicity
- Interstitial lung disease
Important Disclaimer
The Kryxana 200 mg FC tablet. professional information leaflet below is the property of Novartis South Africa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
